Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Processa Pharmaceuticals Announces FDA Clearance for Phase 2 Study of VT-7208, Executive Chair Appointment, and New Collaboration | WAPE

Back All news

Newsfiscal.ai

Processa Pharmaceuticals Announces FDA Clearance for Phase 2 Study of VT-7208, Executive Chair Appointment, and New Collaboration

Oct 30, 2026, 09:04 ET · Published

View source

Article summary

Processa Pharmaceuticals received FDA clearance for a Phase 2 study of its BTK inhibitor VT-7208 in chronic spontaneous urticaria and appointed Dr. Sheila Gujrathi as Executive Chair.

An excerpt from the original article.

Related companies

Processa Pharmaceuticals, Inc. Common StockPCSAView stock

Processa Pharmaceuticals Announces FDA Clearance for Phase 2 Study of VT-7208, Executive Chair Appointment, and New Collaboration

Article summary

Related companies

Analyzed by WAPE AI.

Comments —